Inhibrx Inc

NASDAQ:INBX  
16.71
-0.11 (-0.65%)
Earnings Announcements

Inhibrx Reports Q4 Loss Per Share Of $0.47

Published: 03/12/2021 14:18 GMT
Inhibrx Inc (INBX) - Q4 Loss per Share $0.47.
Observed Dose-limiting Toxicities, Which Were Consistent With Immune Related Adverse Events at Several Dose Levels for Inbrx-105.
Determined 1 Mg/kg Dose Level As Maximum Tolerated Dose of Inbrx-105.
Revenue is expected to be $0.83 Million
Adjusted EPS is expected to be -$0.64

Next Quarter Revenue Guidance is expected to be $0.83 Million
Next Quarter EPS Guidance is expected to be -$0.61

More details on our Analysts Page.